The following guideline can be ordered through the address listed in the "Source/Publisher"-category. In cases in which you can order through the Internet we have established a hyperlink.

FDA Guidance for Industry: NDAs: Impurities in Drug Substances (Feb. 2000)


Freedom of Information Staff, (HFI 35), Food and Drug Administration, Rm. 12 A - 30, 5600 Fishers Lane, Rockville, MD 20857, USA, ,

Document Type:
Guidance for industry
Guideline issued by CDER (FDA) on necessary identification and qualification for NDAs and drug master files of impurities in active substances manufactured by chemical synthesis (monographed and non-monographed drug substances)

Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information